Compare GSK plc (GSK) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Palo Alto Networks Inc — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while Palo Alto Networks Inc trades at $356.36 (market cap $288.53B). The key difference: Palo Alto Networks Inc is far larger — about 2.8× GSK plc's market cap, and GSK plc pays a 3.49% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| GSK | PANW | |
|---|---|---|
Market Cap | $101.34B | $288.53B |
Sector | Health | Technology |
52-Week High | $61.18 | $357.53 |
52-Week Low | $36.20 | $141.67 |
Enterprise Value | $121.95B | $287.49B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Palo Alto Networks (PANW) stock surged 6.84% to $352.89, reflecting strong market momentum amid a sector-wide cybersecurity rally. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. Technical indicators show a bullish trend, while analyst sentiment remains overwhelmingly positive with 74% buy ratings. The company's revenue growth trajectory is solid, projected to reach $10.6B in 2026, though valuation ratios remain elevated with a P/E of 307.84 and P/S of 24.58.
The outlook for PANW is favorable due to accelerating AI-driven cybersecurity demand and strong execution, but risks include premium valuation compression and intensifying competition from Fortinet and Zscaler. While free cash flow generation remains healthy at $3.72B in 2025, the stock trades above the consensus price target of $339.56, suggesting near-term consolidation may precede further gains as the company capitalizes on platformization and AI security tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
